Drug intelligence / Profile preview

E1511

Development stage: Preclinical
Lead developer: Eisai
Modality: Small Molecules

Overview

**E1511** is an in-house small molecule compound developed by Eisai as a clinical candidate for malaria treatment. It acts as a potent inhibitor of GWT1, a protein essential for the survival of Plasmodium parasites, the causative agents of malaria. Discovered through optimization efforts starting in 2010 after identifying GWT1 as a novel target shared with antifungal mechanisms, E1511 was selected in 2021 for clinical development in collaboration with Medicines for Malaria Venture (MMV).[1][3][11]

Targets

GWT1 (Glycosylphosphatidylinositol biosynthesis protein Gwt1)

Beyond the preview

Go deeper on E1511.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E1511.

Explore the full profile